Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Kezar Life Sciences, Inc. completed a disposition involving Enodia Therapeutics SAS for $800,000 in cash at the closing (closed 2026-03-06).
- Action
- disposition
- Counterparty
- Enodia Therapeutics SAS
- Consideration
- $800,000 in cash at the closing
- Closing
- 2026-03-06
Exact text from the filing
assets related to the Company’s zetomizomib program, employee contracts, cash, accounts receivable, real property or equipment. Pursuant to the Agreement, the Company received $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of (i) physical delivery of certain inventory assets to Enodia and (ii) 45 days after the
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kezar Life Sciences, Inc. entered into Asset Purchase Agreement with Enodia Therapeutics SAS valued at $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of ( (effective 2026-03-06).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Enodia Therapeutics SAS
- Value
- $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of (
- Effective
- 2026-03-06
Exact text from the filing
On March 6, 2026, Kezar Life Sciences, Inc. (the “Company”) and Enodia Therapeutics SAS, a French simplified joint stock company (“Enodia”), entered into an asset purchase agreement (the “Agreement”) pursuant to which Enodia (i) acquired all of the Company’s rights, title and interest in the Company’s Sec61-based discovery and development program assets, including the product candidate internally known as KZR-261 (collectively, the “Assets”); and (ii) assumed liabilities from the Company related to certain transferred contracts and from the ownership, use, operation or maintenance of the Assets under the Agreement (the “Transaction”).
View on SEC.gov